A. S. De-groot, L. Moise, and J. A. Mcmurry, Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes", Blood, vol.112, issue.8, pp.3303-3311, 2008.
DOI : 10.1182/blood-2008-02-138073

L. P. Cousens, N. Najafian, and F. Mingozzi, In Vitro and In Vivo Studies of IgG-derived Treg Epitopes (Tregitopes): A Promising New Tool for Tolerance Induction and Treatment of Autoimmunity, Journal of Clinical Immunology, vol.207, issue.9, pp.43-49, 2013.
DOI : 10.1084/jem.20100209

L. P. Cousens, R. Tassone, B. D. Mazer, V. Ramachandiran, D. W. Scott et al., Tregitope update: Mechanism of action parallels IVIg, Autoimmunity Reviews, vol.12, issue.3, pp.436-443, 2012.
DOI : 10.1016/j.autrev.2012.08.017

W. Elyaman, S. J. Khoury, D. W. Scott, and A. S. De-groot, Potential application of Tregitopes as immuno-modulating agents in multiple sclerosis, Neurology Research International, vol.2011, 2011.

Y. Su, R. Rossi, A. S. De-groot, and D. W. Scott, Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se, Journal of Leukocyte Biology, vol.94, issue.2, pp.377-383, 2013.
DOI : 10.1189/jlb.0912441

L. P. Cousens, Y. Su, and E. Mcclaine, Application of IgGderived natural treg epitopes (IgG Tregitopes) to antigenspecific tolerance induction in a murine model of type 1 diabetes, Journal of Diabetes Research, vol.2013, 2013.

C. W. Grant, C. M. Moran-paul, S. K. Duclos, D. L. Guberski, and G. Arreaza-rubín, Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents, PLoS ONE, vol.1150, issue.8, 2013.
DOI : 10.1371/journal.pone.0072989.g009

S. Van-der-marel, A. Majowicz, and K. Kwikkers, Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis, World Journal of Gastroenterology, vol.18, issue.32, pp.4288-4299, 2012.
DOI : 10.3748/wjg.v18.i32.4288

A. Ephrem, S. Chamat, and C. , Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis, Blood, vol.111, issue.2, pp.715-722, 2008.
DOI : 10.1182/blood-2007-03-079947

J. A. Bluestone and A. K. Abbas, Opinion-Regulatory Lymphocytes: Natural versus adaptive regulatory T cells, Nature Reviews Immunology, vol.3, issue.3, pp.253-257, 2003.
DOI : 10.1038/nri1032

]. M. Maddur, S. Othy, and P. Hegde, Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells, Journal of Clinical Immunology, vol.112, issue.S1, pp.4-8, 2010.
DOI : 10.4049/jimmunol.179.8.5571

M. Miyara and S. Sakaguchi, Human FoxP3+CD4+ regulatory T cells: their knowns and unknowns, Immunology and Cell Biology, vol.177, issue.3, pp.346-351, 2011.
DOI : 10.1126/science.1142331

H. Jonuleit, E. Schmitt, H. Kakirman, M. Stassen, J. Knop et al., Infectious Tolerance, The Journal of Experimental Medicine, vol.196, issue.2, pp.255-260, 2002.
DOI : 10.1016/S1074-7613(01)00120-0

D. M. Gravano and D. A. Vignali, The battle against immunopathology: infectious tolerance mediated by regulatory T cells, Cellular and Molecular Life Sciences, vol.180, issue.3, 1997.
DOI : 10.4049/jimmunol.180.3.1792
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3353028

C. N. Baxevanis, C. G. Ioannides, G. J. Reclos, and M. Papamichail, Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function, European Journal of Immunology, vol.39, issue.8, pp.1013-1016, 1986.
DOI : 10.1042/bj1070171

Z. M. Sthoeger, A. Sharabi, and Y. Molad, Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): Immunomodulation of gene expression, Journal of Autoimmunity, vol.33, issue.1, pp.77-82, 2009.
DOI : 10.1016/j.jaut.2009.03.009

Z. Sthoeger, H. Zinger, A. Sharabi, I. Asher, and E. Mozes, The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-í µí»¼ in murine and human systemic lupus erythematosus, PLoS ONE, vol.8, issue.3, 2013.

M. Warncke, M. Buchner, and G. Thaller, Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells, Cancer Immunology, Immunotherapy, vol.6, issue.6, pp.49-60, 2011.
DOI : 10.1038/76243

V. Jawa, L. P. Cousens, M. Awwad, E. Wakshull, H. Kropshofer et al., T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation, Clinical Immunology, vol.149, issue.3, pp.534-555, 2013.
DOI : 10.1016/j.clim.2013.09.006
URL : http://doi.org/10.1016/j.clim.2013.09.006

A. S. De-groot and W. Martin, Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics, Clinical Immunology, vol.131, issue.2, pp.189-201, 2009.
DOI : 10.1016/j.clim.2009.01.009

J. R. Schafer, B. M. Jesdale, J. A. George, N. M. Kouttab, and A. S. De-groot, Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix, Vaccine, vol.16, issue.19, pp.1880-1884, 1998.
DOI : 10.1016/S0264-410X(98)00173-X

C. A. Weber, P. J. Mehta, M. Ardito, L. Moise, B. Martin et al., T cell epitope: Friend or Foe? Immunogenicity of biologics in context?, Advanced Drug Delivery Reviews, vol.61, issue.11, pp.965-976, 2009.
DOI : 10.1016/j.addr.2009.07.001

D. T. Golan and Y. Borel, NONANTIGENICITY AND IMMUNOLOGIC TOLERANCE: THE ROLE OF THE CARRIER IN THE INDUCTION OF TOLERANCE TO THE HAPTEN, Journal of Experimental Medicine, vol.134, issue.4, pp.1046-1061, 1971.
DOI : 10.1084/jem.134.4.1046

E. T. Zambidis and D. W. Scott, Epitope-specific tolerance induction with an engineered immunoglobulin., Proceedings of the National Academy of Sciences, vol.93, issue.10, pp.5019-5024, 1996.
DOI : 10.1073/pnas.93.10.5019
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC39399/pdf

N. Soukhareva, Y. Jiang, and D. W. Scott, Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: Role of T regulatory cells, Cellular Immunology, vol.240, issue.1, pp.41-46, 2006.
DOI : 10.1016/j.cellimm.2006.06.004

L. Song, J. Wang, and R. Wang, Retroviral delivery of GAD-IgG fusion construct induces tolerance and modulates diabetes: a role for CD4+ regulatory T cells and TGF-???, Gene Therapy, vol.11, issue.20, pp.1487-1496, 2004.
DOI : 10.1038/sj.gt.3302327

A. Lobell, R. Weissert, and M. K. Storch, Vaccination with DNA Encoding an Immunodominant Myelin Basic Protein Peptide Targeted to Fc of Immunoglobulin G Suppresses Experimental Autoimmune Encephalomyelitis, The Journal of Experimental Medicine, vol.153, issue.9, pp.1543-1548, 1998.
DOI : 10.1002/eji.1830250812

Y. Su, G. Carey, M. Mari´cmari´c, and D. W. Scott, B Cells Induce Tolerance by Presenting Endogenous Peptide-IgG on MHC Class II Molecules via an IFN-?-Inducible Lysosomal Thiol Reductase-Dependent Pathway, The Journal of Immunology, vol.181, issue.2, pp.1153-1160, 2008.
DOI : 10.4049/jimmunol.181.2.1153
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2587118/pdf

M. El-amine, J. A. Hinshaw, and D. W. Scott, In vivo induction of tolerance by an Ig peptide is not affected by the deletion of FcR or a mutated IgG Fc fragment, International Immunology, vol.14, issue.7, pp.761-766, 2002.
DOI : 10.1093/intimm/dxf049

J. Bayry, K. Bansal, M. D. Kazatchkine, and S. V. Kaveri, DC-SIGN and ?2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells, Proceedings of the National Academy of Sciences, vol.101, issue.39, p.24, 2009.
DOI : 10.1073/pnas.0402183101

R. M. Anthony, F. Nimmerjahn, D. J. Ashline, V. N. Reinhold, J. C. Paulson et al., Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc, Science, vol.310, issue.5753, pp.373-376, 2008.
DOI : 10.1126/science.1118948

R. Bazin, R. Lemieux, and T. Tremblay, Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody, British Journal of Haematology, vol.135, issue.1, pp.97-100, 2006.
DOI : 10.1126/science.291.5503.484

X. Yu, S. Vasiljevic, D. A. Mitchell, M. Crispin, and C. N. Scanlan, Dissecting the Molecular Mechanism of IVIg Therapy: The Interaction between Serum IgG and DC-SIGN is Independent of Antibody Glycoform or Fc Domain, Journal of Molecular Biology, vol.425, issue.8, pp.1253-1258, 2013.
DOI : 10.1016/j.jmb.2013.02.006

D. A. Patel, A. Puig-canto, D. K. Challa, H. P. Montoyo, R. J. Ober et al., Neonatal Fc Receptor Blockade by Fc Engineering Ameliorates Arthritis in a Murine Model, The Journal of Immunology, vol.187, issue.2, pp.1015-1022, 2011.
DOI : 10.4049/jimmunol.1003780

J. G. Routsias, N. C. Kyriakidis, and D. M. Friedman, Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block, Arthritis & Rheumatism, vol.110, issue.9, pp.2783-2789, 2011.
DOI : 10.1097/01.AOG.0000270302.80336.dd

S. C. Jordan, M. Toyoda, and A. A. Vo, Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation, Expert Review of Clinical Immunology, vol.7, issue.3, pp.341-348, 2011.
DOI : 10.1586/eci.11.10

A. Durandy, S. V. Kaveri, and T. W. Kuijpers, Intravenous immunoglobulins - understanding properties and mechanisms, Clinical & Experimental Immunology, vol.111, issue.1, pp.2-13, 2009.
DOI : 10.4049/jimmunol.179.8.5571
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801035

M. S. Maddur, P. Hegde, M. Sharma, S. V. Kaveri, and J. Bayry, B cells are resistant to immunomodulation by ???IVIg-educated??? dendritic cells, Autoimmunity Reviews, vol.11, issue.2, pp.154-156, 2011.
DOI : 10.1016/j.autrev.2011.08.004

M. S. Maddur, S. V. Kaveri, and J. Bayry, Comparison of different IVIg preparations on IL-17 production by human Th17 cells, Autoimmunity Reviews, vol.10, issue.12, pp.809-810, 2011.
DOI : 10.1016/j.autrev.2011.02.007

A. Kessel, H. Ammuri, and R. Peri, Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells, Journal of Immunology The Journal of Allergy and Clinical Immunolog, vol.179, issue.8, pp.5571-5575, 2007.

M. Lopez, M. R. Clarkson, M. Albin, M. H. Sayegh, and N. Najafian, A Novel Mechanism of Action for Anti-Thymocyte Globulin: Induction of CD4+CD25+Foxp3+ Regulatory T Cells, Journal of the American Society of Nephrology, vol.17, issue.10, pp.2844-2853, 2006.
DOI : 10.1681/ASN.2006050422

T. Tha-in, H. J. Metselaar, A. R. Bushell, J. Kwekkeboom, and K. J. Wood, Intravenous Immunoglobulins Promote Skin Allograft Acceptance by Triggering Functional Activation of CD4+Foxp3+ T cells, Transplantation, vol.89, issue.12, pp.1446-1455, 2010.
DOI : 10.1097/TP.0b013e3181dd6bf1

K. L. Legge, J. J. Bell, L. Li, R. Gregg, J. C. Caprio et al., Multi-Modal Antigen Specific Therapy for Autoimmunity, International Reviews of Immunology, vol.5, issue.5, pp.593-611, 2001.
DOI : 10.1016/S1074-7613(00)80309-X

H. Orbach, U. Katz, Y. Sherer, and Y. Shoenfeld, Intravenous Immunoglobulin: Adverse Effects and Safe Administration, Clinical Reviews in Allergy & Immunology, vol.29, issue.3, pp.173-184, 2005.
DOI : 10.1385/CRIAI:29:3:173

B. D. Mazer, S. Al-tamemi, J. W. Yu, and Q. Hamid, Immune supplementation and immune modulation with intravenous immunoglobulin, Journal of Allergy and Clinical Immunology, vol.116, issue.4, pp.941-944, 2005.
DOI : 10.1016/j.jaci.2005.07.021

J. S. Orange, E. M. Hossny, and C. R. Weiler, Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology, Journal of Allergy and Clinical Immunology, vol.117, issue.4, pp.525-553, 2006.
DOI : 10.1016/j.jaci.2006.01.015